T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Methode Electronics
MEI
$593M
| $709K | ﹤0.01% |
16,871
-1,180
| -7% | -$54.1K |
|
|
AGR
2202
DELISTED
Avangrid, Inc.
AGR
| $706K | ﹤0.01% |
14,537
+4,740
| +48% | +$250K |
|
2203
Arcturus Therapeutics
ARCT
$223M
| $704K | ﹤0.01% |
14,741
-119,000
| -89% | -$5.33M |
|
2204
Franklin Covey
FC
$227M
| $704K | ﹤0.01% |
17,257
-1,307
| -7% | -$50.3K |
|
2205
German American Bancorp
GABC
$1.92B
| $704K | ﹤0.01% |
18,228
+38
| +0.2% | +$1.41K |
|
2206
Nu Skin
NUS
$236M
| $700K | ﹤0.01% |
17,307
+36
| +0.2% | +$1.82K |
|
2207
Shift4
FOUR
$3.79B
| $697K | ﹤0.01% |
8,995
+82
| +0.9% | +$7.07K |
|
|
DHIL
2208
DELISTED
Diamond Hill
DHIL
| $696K | ﹤0.01% |
3,963
-6
| -0.2% | -$1.05K |
|
|
OPI
2209
DELISTED
Office Properties Income Trust
OPI
| $695K | ﹤0.01% |
27,435
-108
| -0.4% | -$2.94K |
|
|
UGIC
2210
DELISTED
UGI Corporation
UGIC
| $694K | ﹤0.01% |
6,953
+2,776
| +66% | +$291K |
|
2211
Century Communities
CCS
$2.04B
| $691K | ﹤0.01% |
11,249
+950
| +9% | +$63K |
|
2212
Laureate Education
LAUR
$5.15B
| $691K | ﹤0.01% |
40,695
+8,682
| +27% | +$136K |
|
2213
Pembina Pipeline
PBA
$28.4B
| $691K | ﹤0.01% |
21,809
+144
| +0.7% | +$4.54K |
|
2214
United Fire Group
UFCS
$1.38B
| $691K | ﹤0.01% |
29,905
+6,400
| +27% | +$160K |
|
|
AVYA
2215
DELISTED
Avaya Holdings Corp. Common Stock
AVYA
| $691K | ﹤0.01% |
34,907
+200
| +0.6% | +$4.41K |
|
|
VIVO
2216
DELISTED
Meridian Bioscience Inc
VIVO
| $691K | ﹤0.01% |
35,908
| – | – |
|
|
RVNC
2217
DELISTED
Revance Therapeutics, Inc.
RVNC
| $689K | ﹤0.01% |
24,745
+200
| +0.8% | +$5.71K |
|
|
PRO
2218
DELISTED
PROS Holdings
PRO
| $686K | ﹤0.01% |
19,321
+100
| +0.5% | +$4.2K |
|
|
QUOT
2219
DELISTED
Quotient Technology Inc
QUOT
| $685K | ﹤0.01% |
117,616
+16,765
| +17% | +$140K |
|
|
ENDP
2220
DELISTED
Endo International plc
ENDP
| $682K | ﹤0.01% |
210,431
+51,800
| +33% | +$183K |
|
|
CYBR
2221
DELISTED
CyberArk
CYBR
| $679K | ﹤0.01% |
4,301
+1,200
| +39% | +$182K |
|
2222
iShares Core Dividend Growth ETF
DGRO
$43.9B
| $675K | ﹤0.01% |
13,439
| – | – |
|
2223
CoreCivic
CXW
$3.13B
| $669K | ﹤0.01% |
75,143
-39,636
| -35% | -$386K |
|
|
ADAM
2224
Adamas Trust
ADAM
$907M
| $669K | ﹤0.01% |
39,242
-1,500
| -4% | -$26.1K |
|
2225
Scansource
SCSC
$1.06B
| $669K | ﹤0.01% |
19,242
+111
| +0.6% | +$3.41K |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.